Physician profile
Russell E Brown
NPI 1851581763
$2,077.64
in general payments reported to CMS, 2019-2025
11 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $751 · 2021: $47.67 · 2023: $179 · 2024: $79.65 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $737.75 | 2020 | |
| Dilon Technologies, INC. | $346.35 | 2024-2025 | Hemoblast Bellows |
| Medtronic, INC. | $250.22 | 2021-2025 | Ligasure, Signia |
| Intera Oncology, INC | $201.88 | 2025 | Intera |
| Astrazeneca Pharmaceuticals LP | $117.41 | 2023 | |
| Medical Device Business Services, INC. | $116.28 | 2019 | |
| Boston Scientific Corporation | $91.81 | 2019 | |
| Olympus America INC. | $67.13 | 2019 | |
| Abbvie INC. | $59.96 | 2019-2023 | Creon |
| Bayer Healthcare Pharmaceuticals INC. | $57.28 | 2019-2023 | |
| Davol INC. | $31.57 | 2020-2025 | Channel Drain |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.